Stockscreener 앱 받기
4.05
4.92%
0.19
시장 영업 전:
4.05
전일 마감가:
$3.86
열려 있는:
$3.86
하루 거래량:
880.73K
Relative Volume:
1.56
시가총액:
$284.62M
수익:
$114.70K
순이익/손실:
$-12.82M
주가수익비율:
-1.5149
EPS:
-2.6735
순현금흐름:
$-45.71M
1주 성능:
+8.58%
1개월 성능:
-2.41%
6개월 성능:
+72.34%
1년 성능:
+193.48%
1일 변동 폭
$3.80
$4.08
1주일 범위
$3.65
$4.08
52주 변동 폭
$1.30
$6.60
Sab Biotherapeutics Inc Stock (SABS) Company Profile
명칭
Sab Biotherapeutics Inc
전화
305-845-2813
주소
777 W 41ST ST, MIAMI BEACH
Compare SABS vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SABS
Sab Biotherapeutics Inc
|
4.05 | 284.62M | 114.70K | -12.82M | -45.71M | -2.6735 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 112.35B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.71B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 52.29B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 44.48B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 35.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Sab Biotherapeutics Inc Stock (SABS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-02 | 개시 | Rodman & Renshaw | Buy |
| 2025-12-19 | 개시 | Guggenheim | Buy |
| 2025-09-17 | 개시 | Leerink Partners | Outperform |
| 2025-05-14 | 재개 | H.C. Wainwright | Buy |
| 2024-10-09 | 개시 | Craig Hallum | Buy |
| 2024-08-28 | 개시 | Oppenheimer | Outperform |
| 2021-11-05 | 개시 | Chardan Capital Markets | Buy |
모두보기
Sab Biotherapeutics Inc 주식(SABS)의 최신 뉴스
SAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society Congress - Investing News Network
SAB Biotherapeutics Looks Undervalued If SAB-142 Delivers In Type 1 Diabetes - National Today
New type 1 diabetes data from SAB-142 heads to Brisbane meeting - Stock Titan
SAB BIO to Present Additional Data Supporting the Unique - GlobeNewswire
SABS Price Today: SAB Biotherapeutics, Inc. Stock Price, Quote & Chart | MEXC - mexc.co
Breakouts Watch: Whats the profit margin of SAB Biotherapeutics Inc Equity WarrantWatch List & AI Powered Trade Plan Recommendations - baoquankhu1.vn
Published on: 2026-04-12 12:29:27 - baoquankhu1.vn
Investment Report: Will SAB Biotherapeutics Inc outperform during market rallies2026 PostEarnings & High Win Rate Trade Tips - baoquankhu1.vn
SABS Options Volatility — NASDAQ:SABS - TradingView — Track All Markets
Aug Chart Watch: Will SAB Biotherapeutics Inc stock recover after earnings2026 Sector Review & Real-Time Volume Triggers - baoquankhu1.vn
EV Market: Will SAB Biotherapeutics Inc outperform during market ralliesWeekly Risk Report & Precise Trade Entry Recommendations - baoquankhu1.vn
Trading Action: Is Sinclair Incs growth already priced inQuarterly Growth Report & Weekly Hot Stock Watchlists - baoquankhu1.vn
Insider Trends: Is SAB Biotherapeutics Inc being accumulated by smart moneyMarket Risk Report & Stock Portfolio Risk Management - baoquankhu1.vn
Trading Recap: Is HADPP showing insider buyingQuarterly Market Summary & Growth Focused Entry Point Reports - baoquankhu1.vn
SAB Biotherapeutics (NASDAQ:SABS) Coverage Initiated at Rodman & Renshaw - MarketBeat
Rodman & Renshaw initiates SAB Biotherapeutics stock with buy rating By Investing.com - Investing.com Canada
Rodman & Renshaw initiates SAB Biotherapeutics stock with buy rating - Investing.com
SABSW SEC FilingsSAB BIOTHERAPEUTICS INC 10-K, 10-Q, 8-K Forms - Stock Titan
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Short Interest Up 21.1% in March - MarketBeat
Published on: 2026-03-30 20:34:02 - baoquankhu1.vn
Published on: 2026-03-27 23:19:55 - baoquankhu1.vn
Institution Moves: Is SAB Biotherapeutics Inc stock a smart retirement pickIPO Watch & Pattern Based Trade Signal System - baoquankhu1.vn
SAB Biotherapeutics (SABS) CMO has common shares withheld for taxes - Stock Titan
United StatesMintz Advises On SAB Biotherapeutics’ $85 Million Public Offering - Mondaq
SAB Biotherapeutics - Global Legal Chronicle
[SCHEDULE 13D/A] SAB Biotherapeutics, Inc. Amended Major Shareholder Report - Stock Titan
SAB Biotherapeutics Completes $85 Million Public Offering - Global Legal Chronicle
SAB Biotherapeutics closes $85 million public offering - The Pharma Letter
SAB Biotherapeutics (SABS) to Release Earnings on Friday - marketbeat.com
SAB Biotherapeutics announces public stock offering; shares down - MSN
SAB Biotherapeutics Closes $85 Million Securities Offering - marketscreener.com
SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants - Weekly Voice
SAB Biotherapeutics (SABS) raises $69.7M net to advance SAB‑142 clinical program - Stock Titan
SAB Biotherapeutics Launches Major Equity Financing Offering - TipRanks
SAB Biotherapeutics (NASDAQ: SABS) to raise $85M for SAB-142 trials - Stock Titan
SAB Biotherapeutics Prices Underwritten Equity Offering; About $69.7 Million Net Proceeds Expected - TradingView
Stock Recap: Is SAB Biotherapeutics Inc being accumulated by smart money2026 Market Outlook & Low Volatility Stock Recommendations - baoquankhu1.vn
Guggenheim initiates coverage of SAB Biotherapeutics (SABS) with buy recommendation - MSN
SAB Biotherapeutics prices $85M stock offering at $3.85/share By Investing.com - Investing.com South Africa
SAB Biotherapeutics prices $85M stock offering at $3.85/share - Investing.com
Sab Bio announces pricing of $85 million public offering of common stock at $3.85 per share - marketscreener.com
SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants - The Manila Times
SAB Biotherapeutics, Inc. Prices Public Offering of Common Stock and Pre-Funded Warrants to Raise Approximately $85 Million - quiverquant.com
SAB BIO plans $85M funding push for experimental type 1 diabetes treatment - Stock Titan
SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants - Benzinga
SAB Biotherapeutics (SABS) to offer common stock and pre-funded warrants - Stock Titan
SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - The Manila Times
Biotech SAB BIO plans stock sale to fund Type 1 diabetes trials - Stock Titan
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Short Interest Update - MarketBeat
Commodore Capital LP Takes Position in SAB Biotherapeutics, Inc. $SABS - MarketBeat
SAB Biotherapeutics (NASDAQ:SABS) Cut to “Strong Sell” at Zacks Research - Defense World
Sab Biotherapeutics Inc (SABS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Sab Biotherapeutics Inc 주식 (SABS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Sessa Capital (Master), L.P. | Director |
Sep 29 '25 |
Option Exercise |
1.75 |
1,740,000 |
3,045,000 |
2,198,457 |
2.69%
0.25%
자본화:
|
볼륨(24시간):